aTYR PHARMA INC (ATYR): Nasdaq/NYSE listing notice — aTyr Pharma receives Nasdaq bid-price deficiency notice; 180 days to cure

aTYR PHARMA INC

On Dec 4, 2025, Nasdaq notified ATYR that its common stock closed below $1.00 for 30 consecutive business days.
Company has until June 2, 2026 to regain compliance with Nasdaq Listing Rule 5550(a)(2).
If not cured, may be eligible for a second 180-day period by meeting other initial listing standards.
Company may consider a reverse stock split if needed to cure the deficiency.
Failure to regain compliance could lead to delisting and an appeal process.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

aTYR PHARMA INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

December 4, 2025, aTyr Pharma, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the listing qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days preceding the date of the Notice, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Company’s common stock on The Nasdaq Capital Market. In acc

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

aTYR PHARMA INC filing history →

Source: SEC EDGAR

accession 0001193125-25-309619

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.